Literature DB >> 10542947

Frequent allelic imbalance of tumor suppressor gene loci in cervical dysplasia.

F Luft1, J Gebert, A Schneider, P Melsheimer, M von Knebel Doeberitz.   

Abstract

In addition to human papillomavirus (HPV) infection, loss of heterozygosity (LOH) at tumor suppressor gene loci has been frequently observed in cervical cancer. Thus, it may be assumed that detection and characterization of specific LOH profiles in preneoplastic lesions, in addition to HPV typing, might facilitate assessment of progression risk of cervical dysplasia. In this study, the type and frequency of allelic imbalance (allelic loss or allelic reduction) were analyzed in 24 unrelated cervical lesions using 14 polymorphic microsatellite markers at different tumor suppressor gene loci. No allelic loss was observed in four condylomatous lesions, whereas 2 of 13 (15%) CIN I lesions displayed allelic loss at 3p25 and 5q11-13. In high-grade lesions, however, allelic loss occurred in four of six (66%) cases at multiple chromosomal regions (3p14-25, 5p15, 5q11, 5q21, 11p15, and 17q21). Allelic reduction was observed in 4 of 13 (30%) low-grade lesions and 3 of 6 (50%) high-grade lesions. LOH was confined to lesions infected by high-risk HPV types. These data suggest that chromosomal instability is an early event in cervical carcinogenesis. The detection of LOH on multiple chromosome 3p loci in 50% of high-grade lesions suggests that a specific marker panel encompassing this region might enable better assessment of which lesions are likely to regress, persist, or progress.

Entities:  

Mesh:

Year:  1999        PMID: 10542947     DOI: 10.1097/00004347-199910000-00013

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family.

Authors:  Liang Liang; Mujun Zhao; Zhenhua Xu; Kazunari K Yokoyama; Tsaiping Li
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

2.  Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: a pilot study.

Authors:  Monika Migdalska-Sęk; Agata Karowicz-Bilińska; Dorota Pastuszak-Lewandoska; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska-Senderowska; Justyna Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-04-18       Impact factor: 3.064

3.  The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.

Authors:  Enrique Zudaire; Natalia Cuesta; Vundavalli Murty; Karen Woodson; Lisa Adams; Nieves Gonzalez; Alfredo Martínez; Gopeshwar Narayan; Ilan Kirsch; Wilbur Franklin; Fred Hirsch; Michael Birrer; Frank Cuttitta
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

4.  Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations.

Authors:  Willem Ernst Corver; Natalja Tatjana Ter Haar; Gert Jan Fleuren; Jan Oosting
Journal:  Cell Oncol (Dordr)       Date:  2011-11-01       Impact factor: 6.730

5.  Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions.

Authors:  Hugo Arias-Pulido; Gopeshwar Narayan; Hernan Vargas; Mahesh Mansukhani; Vundavalli V V S Murty
Journal:  Mol Cancer       Date:  2002-10-01       Impact factor: 27.401

6.  Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma.

Authors:  Pulivarthi H Rao; Hugo Arias-Pulido; Xin-Yan Lu; Charles P Harris; Hernan Vargas; Fang F Zhang; Gopeshwar Narayan; Achim Schneider; Mary Beth Terry; Vundavalli V V S Murty
Journal:  BMC Cancer       Date:  2004-02-06       Impact factor: 4.430

7.  Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome.

Authors:  W Alazawi; M Pett; S Strauss; R Moseley; J Gray; M Stanley; N Coleman
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.